| Drug ID: | Drug107 |
|---|---|
| Drug Name: | Talabostat |
| CID: | 6918572 |
| DrugBank ID: | DB06182 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NULL |
| Molecular Formula: | C9H19BN2O3 |
| Molecular Weight: | 214.07 g/mol |
| Isomeric SMILES: | B([C@@H]1CCCN1C(=O)[C@H](C(C)C)N)(O)O |
| Synonyms: | Talabostat; 149682-77-9; Val-boroPro; [(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid; KZ1O2SH88Z; CHEMBL67279; L-valinyl-L-boroproline; ((R)-1-(L-Valyl)pyrrolidin-2-yl)boronic acid; Pyrrolidine derivative; PT100 |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt909 | 6918572 | Talabostat | 2191 | FAP | Homo sapiens (human) | None | |
| dt910 | 6918572 | Talabostat | 2357 | FPR1 | Homo sapiens (human) | Inhibitor | |
| dt911 | 6918572 | Talabostat | 1612 | DAPK1 | Homo sapiens (human) | Inhibitor | |
| dt912 | 6918572 | Talabostat | 1803 | DPP4 | Homo sapiens (human) | 18783201 | Inhibition |
| dt913 | 6918572 | Talabostat | 54878 | DPP8 | Homo sapiens (human) | 18783201 | Inhibition |
| dt914 | 6918572 | Talabostat | 91039 | DPP9 | Homo sapiens (human) | 18783201 | Inhibition |
| dt915 | 6918572 | Talabostat | 2356 | FPGS | Homo sapiens (human) | Inhibitor | |
| dt916 | 6918572 | Talabostat | 1440 | CSF3 | Homo sapiens (human) | None | |
| dt917 | 6918572 | Talabostat | 2191 | FAP | Homo sapiens (human) | 37713619 | Inhibitor |
| dt918 | 6918572 | Talabostat | 91039 | DPP9 | Homo sapiens (human) | 37713619 | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations